Clinical Trials
28 trialsA Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc.
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
Celgene
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Hebei Yanda Ludaopei Hospital
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
CARFI
Aalborg University Hospital
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
TMI-ASCT
Ottawa Hospital Research Institute
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
National Cancer Institute (NCI)
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
Gruppo Italiano Studio Linfomi
MM03
University of Regensburg
Bortezomib and High-dose Melphalan at Myeloma Relapse
Nordic Myeloma Study Group